Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from PainReform ( (PRFX) ).
On December 30, 2025, PainReform Ltd. convened its Annual General Meeting of Shareholders in Tel Aviv but was unable to proceed with the meeting’s agenda due to a lack of quorum. As a result, the company adjourned the meeting for one week and scheduled it to be reconvened on January 6, 2026, at the same time and location at its legal counsel’s offices in Tel Aviv, signaling a minor procedural delay in its routine corporate governance process but no announced changes to operations or strategy.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is driven primarily by very weak financial performance (minimal revenue, widening losses, and worsening cash burn with a shrinking equity cushion). Technicals also weigh on the score due to a clear downtrend versus key moving averages, partially offset by oversold indicators. Valuation contributes little support given negative earnings and no dividend yield.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
Average Trading Volume: 322,652
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.84M
For an in-depth examination of PRFX stock, go to TipRanks’ Overview page.